These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8247794)

  • 1. The manufacture and molecular characterization of phosphorothioate deoxynucleotides for use as antisense therapeutics in human clinical trials.
    Bergot BJ; Foy M; Hansen C; Fearon K; Frediani J; Hirschbein B
    Nucleic Acids Symp Ser; 1993; (29):57. PubMed ID: 8247794
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
    Cho-Chung YS
    Curr Opin Investig Drugs; 2002 Jun; 3(6):934-9. PubMed ID: 12137417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
    Chi KN; Zoubeidi A; Gleave ME
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
    Klisovic RB; Stock W; Cataland S; Klisovic MI; Liu S; Blum W; Green M; Odenike O; Godley L; Burgt JV; Van Laar E; Cullen M; Macleod AR; Besterman JM; Reid GK; Byrd JC; Marcucci G
    Clin Cancer Res; 2008 Apr; 14(8):2444-9. PubMed ID: 18413836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribonucleotides: the unusual chemistry and biochemistry of DNA precursors.
    Follmann H
    Chem Soc Rev; 2004 May; 33(4):225-33. PubMed ID: 15103404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G3139, a BCL-2 antisense oligo-nucleotide, in AML.
    Marcucci G; Stock W; Dai G; Klisovic MI; Maharry K; Shen T; Liu S; Sher DA; Lucas D; Zwiebel A; Larson RA; Caligiuri MA; Bloomfield CD; Chan KK; Grever MR; Byrd JC
    Ann Hematol; 2004; 83 Suppl 1():S93-4. PubMed ID: 15124691
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene therapy: a molecular approach to cancer treatment.
    Anklesaria P
    Curr Opin Mol Ther; 2000 Aug; 2(4):426-32. PubMed ID: 11249773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genta initiates trials with Genasense.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113068
    [No Abstract]   [Full Text] [Related]  

  • 12. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
    Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
    Ravikumar VT; Andrade M; Carty RL; Dan A; Barone S
    Bioorg Med Chem Lett; 2006 May; 16(9):2513-7. PubMed ID: 16481168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates).
    Stec WJ; Grajkowski A; Koziolkiewicz M; Uznanski B
    Nucleic Acids Res; 1991 Nov; 19(21):5883-8. PubMed ID: 1945876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: StealthVector (HIV) Enzo.
    Günzburg W; Mhashilkar AM; Hindi M
    Curr Opin Mol Ther; 1999 Oct; 1(5):651-7. PubMed ID: 11249672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on antisense therapy for the prevention of restenosis.
    Kipshidze N; Moses J; Shankar LR; Leon M
    Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.